The Invossa rollercoaster continues; class action lawsuit started; critics claim the arthritis treatment is ineffective

There has been a flurry of reports from South Korean news outlets relating to the Invossa GP-293 cell mislabeling incident, and this article is meant to be a summary of those reports. Kolon Life Science is being sued Oh Kims Law & Company has started a class action lawsuit against Kolon Life Sciences over injections of...

Kolon confirms existence of questionable GP-293 cells in cartilage regenerating drug, Invossa. Regulatory approval up in the air

The punches keep coming for Kolon Life Science. Not only has their breakthrough cartilage regrowth drug, Invossa, been suspended from sale in their home market of South Korea, but they have also confirmed the existence of GP-293 cells in their most recent batch of the drug. GP-293 cells are derivatives of HEK-293 cells. HEK-293 cells are well known to differentiate...
Chinese Academy of Sciences zoology building

Chinese scientists discover that stem cell regulator CBX4 may prove an effective target for osteoarthritis treatment

Scientists from the Institute of Biophysics of the Chinese Academy of Sciences, Peking University, and the Institute of Zoology of the Chinese Academy of Sciences have found that a protein named CBX4 acts as a regulator of mesenchymal stem cell cellular aging, and senescence. This research is a first in understanding the depth of CBX4's role in aging,...
Invossa Vials

Invossa has lost it’s regulatory approval in South Korea

Today, Kolon Life Sciences ordered an emergency stop-sale on distribution and sales of their pioneering cartilage regeneration drug, Invossa. KLS CEO Lee Woo-suk held a press conference explaining the reason for the temporary withdrawal - an ingredient in Invossa's formulation was mislabeled as originating from a chondrocyte cell, instead of a kidney cell. This discrepancy...